F. Hoffmann-La Roche Ltd.

In News

Roche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical Technology

Pharmaceutical Technology - Jun 08, 2026

Roche enters into a definitive merger agreement to acquire PathAI to transform AI-driven diagnostics - GlobeNewswire

GlobeNewswire - May 07, 2026

F. Hoffmann-La Roche Ltd - Via Ritzau

Via Ritzau - Jun 18, 2026

China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche - Reuters

Reuters - Oct 16, 2025

Nurix Therapeutics, Inc., F. Hoffmann-La Roche Ltd., and Genentech, Inc. Enter Global License and Collaboration Agreement to Co-Develop and Commercialize Bexobrutideg - marketscreener.com

marketscreener.com - Jun 08, 2026

Roche reports new TREM2 agonists - BioWorld News

BioWorld News - May 20, 2026

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer - GlobeNewswire

GlobeNewswire - Jun 11, 2026

Roche receives FDA approval for the first companion - GlobeNewswire

GlobeNewswire - Jun 12, 2026

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology - GlobeNewswire

GlobeNewswire - Jun 08, 2026

Roche inaugurates new research home for the Institute of - GlobeNewswire

GlobeNewswire - Mar 23, 2026

Roche to present new data advancing its obesity portfolio - GlobeNewswire

GlobeNewswire - Jun 01, 2026

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting - GlobeNewswire

GlobeNewswire - Jun 02, 2026

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment